United States / English

EMD Millipore is now MilliporeSigma

Biotech Startup Funding

Primary Need

Lack of funding is one of the main reasons for failure of a biologic.

Estimates vary, but some project it costs $8-10 million just to get to IND stage, another $8-10 million for Phase I, and $20-40 million for Phase II, depending on design. Phase III costs considerably more.

Don’t let a good drug go to waste, or too much of its value to third parties, because of funding issues. There are ways to fund biotech, from biotech crowdfunding, nondilutive funding, and nonsoursive funding, to biotech grants, angel investors, venture capital and other resources.

Funding Sources in China

More to Explore...

2017 - MilliporeSigma's Start-Up Program at LabCentral:
Learn more >

Intellectual Property
Watch emerging biotech CEOs share their intellectual property experiences.

Regulatory Guidance
On the journey to commercialization, be sure to stay the course by understanding the global pharmaceutical regulatory landscape.

The Drug Candidate Journey
The journey from large molecule to approved biotherapeutic is long, costly, complex, and fraught with risk – yet tempting with reward.

Emerging Biotech: Stay Current

Emerging Biotech Upstream Forum
Speed to clinic: direct route from cell line to bioreactor

Join us and your peers for the Emerging Biotech Upstream Forum to discuss latest trends, innovations, and technologies to help you speed up your molecule to clinic: from cell line development to bioreactor scale-up.

Tuesday, November 14, 2017
San Francisco, CA
Hilton Garden Inn, San Francisco Airport North,
670 Gateway Boulevard

Thursday, November 16, 2017
San Diego, CA
DoubleTree Del Mar, 11915 El Camino Real


2017 MilliporeSigma's Start-Up Program
at LabCentral

Winner of LabCentral residency opportunity to be announced soon. We understand the challenges emerging biotech companies face in the quest to push the next generation of drugs to market. It’s our mission to help you succeed! That’s why we’ve partnered with LabCentral - a private non-profit organization designed as a launchpad for high-potential biotech start-ups located in Cambridge, Massachusetts - to sponsor a biotech start-up for a one year residency. Stay tuned to find out who will be selected as the winner of this great opportunity! emdmillipore.com/start-up-program

Online application and rules>

Find out more about our programs:

Bringing your molecule to market. As part of our commitment to meet the needs of the life science community, we’ve developed several programs that recognize stand-out emerging biotech companies. These programs are designed to support biotech start-ups and medium sized companies in solving their current bioprocess development challenges to bring the next generation of molecules to market.

More details about EB Programs>

UPCOMING WEBINAR: Venture Capital Funding: An Insider’s View

Learn more about the ABCs of venture capital including how it works and the role of a corporate venture capital.

Register Now >

WEBINAR: Accelerated ADC Development with Integrated Supply Chain Solutions

Learn more about the advantages to work with one source on your mAb, linker/ payload supplies and conjugation services.

Watch Now >

WEBINAR: RNA Based Therapeutics and Vaccines: Bioprocessing Technology Trends

Review the current dynamics in the RNA therapeutics/vaccines market with a focus on process development and manufacturing strategies.

Watch this Webinar >

WEBINAR: Managing Process Scale-up and Tech Transfer

Learn more on points to consider for successful tech transfers with a focus on cGMP training requirements.

Watch this Webinar >

Webinars On-Demand >


Join us for a discussion that will bring together viral clearance experts to exchange scientific knowledge and strategies.

Register Now >

WHITE PAPER: 2017 Life Science Executive Summit

Establishing an open dialog within the biotech community....

Read more and download >

The Changing Biopharma Risk Equation

A report from the The Economist Intelligence Unit sponsored by MilliporeSigma.
This paper, which incorporates the results of a survey of 254 pharmaceutical executives from around the world and a range of interviews with industry experts, explores in detail global pharmaceutical companies' growth strategies and their plans for managing the associated risks.

Read the study >

Contact Us

Research. Development. Production.

We are a leading supplier to the global Life Science industry: solutions and services for research, development and production of biotechnology and pharmaceutical drug therapies.

© 2017 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.
EMD Millipore is a part of Merck KGaA, Darmstadt, Germany.